Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | LOX | P28300 | 2/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14483776 | 0.92 | ALDH1A1 (0.60) | HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL3449695 | 0.87 | KMT2A (0.44) | HPGDALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL29588558 | 0.86 | PRSS1 (0.50) | HPGDALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL20378006 | 0.86 | PRSS1 (0.50) | HPGDALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL1233804 | 0.85 | L3MBTL1 (0.65) | HPGDALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL15985305 | 0.84 | KMT2A (0.50) | ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL19478089 | 0.83 | SMN1; SMN2 (0.52) | HPGDALDH1A1SMN1; SMN2EPHX2 | |
| SCHEMBL5083356 | 0.83 | HPGD (0.51) | HPGDALDH1A1SMN1; SMN2LOXL3MBTL1 | |
| SCHEMBL177577 | 0.82 | SMN1; SMN2 (0.74) | ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL2555324 | 0.82 | SMN1; SMN2 (0.51) | ALDH1A1SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2025-06-24 | — | — | US | disclosed |
| US-20240287020-A1 | SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2024-08-29 | — | — | US | disclosed |
| US-11970474-B2 | Substituted benzodiazoles and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2024-04-30 | — | — | US | disclosed |
| CN-112074511-B | Substituted benzodiazoles and their use in therapy | 托马斯·黑勒戴药物研究基金会 | 2024-04-26 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| US-20210002250-A1 | SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2021-01-07 | — | — | US | disclosed |
| EP-3759091-A1 | SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY | Thomas Helledays stiftelse för medicinsk forskning (SE) | 2021-01-06 | — | — | EP | disclosed |
| CN-112074511-A | Substituted benzodiazoles and their use in therapy | 托马斯·黑勒戴药物研究基金会 | 2020-12-11 | — | — | CN | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| US-20110015157-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals ,Inc. | 2011-01-20 | — | — | US | disclosed |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| EP-2183228-A1 | CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2010021680-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| EP-2134685-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | Abbott Laboratories (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2124913-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| US-20090124616-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2009017664-A1 | CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008130970-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008077597-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124616-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, API5 | HPGD 3056/4885ALDH1A1 2621/4885TP53 50/4885 |
| US-11970474-B2 | Substituted benzodiazoles and use thereof in therapy | XDH, CYP4X1, CYP11B2 | HPGD 1382/4885ALDH1A1 330/4885TP53 2748/4885 |
| US-20240287020-A1 | SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY | XDH, CYP11B2, CYP4X1 | HPGD 1494/4885ALDH1A1 274/4885TP53 2912/4885 |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | FGFR3, FGFR1, FGFR2 | HPGD 1246/4885ALDH1A1 1131/4885TP53 80/4885 |
| US-20110015157-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | HPGD 52/4885ALDH1A1 98/4885TP53 4329/4885 |
| US-20210002250-A1 | SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY | XDH, CYP4X1, CYP11B2 | HPGD 1382/4885ALDH1A1 330/4885TP53 2748/4885 |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | XDH, CYP11B2, CYP4X1 | HPGD 1494/4885ALDH1A1 274/4885TP53 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.